Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ Study of Chiauranib Plus Albumin-paclitaxel and Gemcitabine as First-line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06492915 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.

NCT NCT06492915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06492915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ Study of Chiauranib Plus Albumin-paclitaxel and Gemcitabine as First-line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Chipscreen Biosciences, Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 13, 2024
Completion date
October 31, 2026
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma